All News
Filter News
Found 808,690 articles
-
GE Healthcare and AMC Health to Partner in Remote Patient Monitoring to Provide Patients with Chronic and Post-Acute Care in the Home
10/19/2022
GE Healthcare and AMC Health today announced a collaboration that allows clinicians to offer Remote Patient Monitoring (RPM) as a virtual care solution that extends patient care outside the hospital to the home environment.
-
Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
10/19/2022
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the company’s U.S. 11,459,351 patent (the ‘351 patent) was granted by the U.S. Patent and Trademark Office.
-
Covis Pharma Reports on FDA Advisory Committee Hearing for Makena®
10/19/2022
Covis Pharma Group (the “Company”), today reported that the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) voted to recommend that the FDA pursue withdrawal of approval of Makena® (hydroxyprogesterone caproate injection).
-
Maravai LifeSciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation
10/19/2022
Executive Chairman and former CEO of Maravai LifeSciences, Inc. (NASDAQ: MRVI) Carl Hull, has been reinstated as CEO of the company on an interim basis.
-
Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults
10/19/2022
Everest Medicines announced today that its partner Providence Therapeutics Holdings Inc. ("Providence") reported positive top-line data from a Phase 2 study evaluating the safety, tolerability and immunogenicity of its mRNA COVID-19 vaccine candidate, PTX-COVID19-B.
-
Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada
10/19/2022
Sebela Pharmaceuticals® has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan in the United States and Canada.
-
Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma
10/19/2022
Bristol Myers Squibb announced results from the Phase 3 CheckMate -76K trial, in which Opdivo as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival versus placebo in patients with completely resected stage IIB or IIC melanoma.
-
Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study
10/19/2022
Kintara Therapeutics, Inc. announced today that the REM-001 program in Cutaneous Metastatic Breast Cancer (CMBC) was paused to conserve cash which will be used to support the funding of the Company's ongoing international registrational study for VAL-083 in glioblastoma (GBM).
-
Providence Announces Positive Top-Line Data from Phase 2 Primary Immunization Trial of its mRNA Vaccine Candidate PTX-COVID19-B in Adults
10/19/2022
Providence Therapeutics Holdings Inc. ("Providence") today announced positive top-line data from the PRO-CL-002 Phase 2 study evaluating the safety, tolerability and immunogenicity of its mRNA COVID-19 vaccine candidate, PTX-COVID19-B.
-
Preclinical Data from iECURE’s GTP-506 Demonstrates Potential for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
10/19/2022
iECURE today announced that data presented at the International Conference on Ureagenesis Defects and Allied Conditions 2022 by its research collaborators led by James Wilson.
-
Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development
10/19/2022
Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services.
-
Anji Pharma and Population Health Partners Enter into Strategic Collaboration to Jointly Address High Prevalence Human Disease
10/19/2022
Anji Pharmaceuticals and Population Health Partners today announced that they have entered into a strategic collaboration, bringing together two complementary teams to jointly address high prevalence human diseases.
-
AnHeart Therapeutics Expands US Team with Appointments in Clinical Research and Medical Affairs
10/19/2022
AnHeart Therapeutics today announced the appointments of Heinrich Farin, M.D. as Senior Medical Director, Clinical Research and Michael J. Humphries, Ph.D., as VP, Head of US Medical Affairs.
-
Analysis Shows Moderna’s Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster
10/19/2022
Moderna, Inc. today announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214.
-
Treatment of Severe Heart Failure - AI: FineHeart Awarded €2.5 million Grant Under the Prestigious EIC Accelerator Program, the First Part of Blended Financing of up to €17.5 Million for the Development & Clinical Trials of the ICOMS FLOWMAKER®
10/19/2022
FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, announced that it had been awarded a €2.5 million grant by the European Commission under the highly selective EIC Accelerator program.
-
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune
10/19/2022
INmune Bio, Inc.(NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces positive solid tumor data in multiple cancer lines resistant to NK killing that can be overcome with administration of INKmune.
-
Sinaptica Therapeutics Announces FDA Breakthrough Device Designation for its Novel Noninvasive Neurostimulation Treatment for Alzheimer’s Disease
10/19/2022
Sinaptica Therapeutics, Inc today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s investigational SinaptiStim™ – AD System for the treatment of cognitive and functional decline in patients diagnosed with Alzheimer’s disease (AD).
-
Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program
10/19/2022
Trethera Corporation announced that the National Eye Institute, a division of the National Institutes of Health, has awarded Trethera a $1.6 million Fast-Track STTR commercialization grant to further develop TRE-515 as a treatment for optic neuritis.
-
Vivasc Therapeutics Inc. Receives Its Second NIH Phase I STTR Grant With the Goal of Reversing the Molecular Causes of Heart Failure
10/19/2022
Vivasc Therapeutics Inc. is pleased to announce it has initiated its second NIH Phase I STTR research grant, in conjunction with Georgetown University.
-
Journal of Clinical Oncology Publishes Positive Results on Large-scale Implementation of Canopy's ePRO-Based Monitoring Platform
10/19/2022
Canopy, the first Intelligent Care Platform for oncology, today announced results from a seventeen-month, real-world study of their ePRO-based patient monitoring platform.